Incyte Corp (INCY)

Add to Watchlists
Create an Alert
Quickflows
80.54 -0.85  -1.04% NASDAQ May 11, 10:30 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All INCY News

News

View All Events

Events

Date Type Description
08/04/2021 07:00 Earnings Results Q2 2021 Earnings Results
08/04/2021 08:00 Earnings Calls Q2 2021 Earnings Call
05/04/2021 07:00 EDT Earnings Results Q1 2021 Earnings Results
05/04/2021 08:00 EDT Earnings Calls Q1 2021 Earnings Call
02/09/2021 07:00 EST Earnings Results Q4 2020 Earnings Results
02/09/2021 08:00 EST Earnings Calls Q4 2020 Earnings Call
11/05/2020 00:00 Earnings Results Q3 2020 Earnings Results
11/05/2020 08:00 EST Earnings Calls Q3 2020 Earnings Call
08/04/2020 08:00 EDT Earnings Calls Q2 2020 Earnings Call
08/04/2020 07:00 EDT Earnings Results Q2 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 2.703B
Total Expenses (TTM) 2.182B
Net Income (TTM) 478.48M

Balance Sheet View Statement

Total Assets (Quarterly) 3.661B
Total Liabilities (Quarterly) 933.59M
Shareholders Equity (Quarterly) 2.728B

Cash Flow Statement View Statement

Cash from Operations (TTM) 764.91M
Cash from Investing (TTM) -220.19M
Cash from Financing (TTM) 82.04M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
  • URL: https://www.incyte.com
  • Investor Relations URL: http://www.incyte.com/ir/investor-overview.aspx
  • HQ State/Province: Delaware
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Aug. 04, 2021
  • Last Earnings Release: May. 04, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 80.54
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.34%
BBH VanEck Vectors Biotech ETF 3.14%
ARKG ARK Genomic Revolution ETF 2.97%
TMIFX Transamerica Mid Cap Growth R4 2.60%
VGHCX Vanguard Health Care Inv 1.74%
IBB iShares Nasdaq Biotechnology ETF 1.55%
TDB875 TD Health Sciences Fund - O 1.33%
F00000MS5P JHFunds2 Health Sciences NAV 1.28%
THISX T. Rowe Price Health Sciences I 1.24%
XBI SPDR® S&P Biotech ETF 0.76%
LABU Direxion Daily S&P Biotech Bull 3X ETF 0.61%
FMEIX Fidelity® Mid Cap Enhanced Index 0.60%

Comparables

Edit
LLY Eli Lilly and Co
REGN Regeneron Pharmaceuticals Inc
VRTX Vertex Pharmaceuticals Inc
BIIB Biogen Inc
SAGE Sage Therapeutics Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.